Coherus Oncology (CHRS) Revenue (2013 - 2026)

Coherus Oncology's Revenue history runs 13 years deep, the most recent figure standing at $12.3 million for Q1 2026.

• In Q1 2026, Revenue rose 61.99% year-over-year to $12.3 million; the TTM figure through Mar 2026 stood at $46.9 million (up 47.99% YoY), while the FY2025 annual figure was $42.2 million, up 59.81% from the prior year.
• Revenue came in at $12.3 million for Q1 2026 at Coherus Oncology, down from $12.7 million in the prior quarter.
• In the past five years, Revenue ranged from a high of $91.5 million in Q4 2023 to a low of $2.3 million in Q1 2024.
• A 5-year average of $32.3 million and a median of $12.7 million in 2025 frame the typical range for Revenue.
• Across the five-year window, Revenue slumped 92.88% in 2024 and jumped 229.25% in 2025, its largest moves.
• Coherus Oncology's Revenue stood at $45.4 million in 2022, then soared by 101.81% to $91.5 million in 2023, then plunged by 91.55% to $7.7 million in 2024, then jumped by 64.85% to $12.7 million in 2025, then decreased by 3.44% to $12.3 million in 2026.
• According to Business Quant data, Revenue over the past three periods registered $12.3 million, $12.7 million, and $11.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison